MedTrace Logo

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

NCT04625699 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-06-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether it is feasible and safe to give research participants investigational treatment with durvalumab and tremelimumab after they have completed standard treatment for NSCLC and once they have detectable circulating tumor DNA (ctDNA) in the blood before there is evidence of disease recurrence on imaging studies. These investigational agents are a type of immunotherapy, which is a treatment that activates your own body's immune system to treat cancer.

Conditions

  • Nonsmall Cell Lung Cancer

Interventions

DRUG

Durvalumab

4 doses of Durvalumab 1500 mg IV Day 1, q28 days (For example, interventions involving drugs may include dosage form, dosage, frequency, and duration.)

DRUG

Tremelimumab

2 doses of Tremelimumab 300 mg IV Day 1, q56 days

Sponsors & Collaborators

  • Catherine Shu

    lead OTHER

Principal Investigators

  • Catherine Shu, MD · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-31
Primary Completion
2023-07-31
Completion
2023-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04625699 on ClinicalTrials.gov